Table 1 Baseline characteristics of the study population
|  | Total (n = 713) |
|---|---|
Demographics | |
 Age, year | 49.88 ± 13.04 |
 Male, n (%) | 424 (59.5%) |
 TyG index | 8.70 ± 0.47 |
 BMI (kg/m2) | 25.55 ± 6.0 |
 Systolic BP (mmHg) | 118.90 ± 18.44 |
 Diastolic BP (mmHg) | 72.64 ± 11.37 |
 Heart Rate (bpm) | 71.49 ± 10.17 |
 NT-proBNP (fmol/mL) | 1910.23 ± 1743.37 |
 Cr (µmol/L) | 76.30 ± 21.13 |
 Uric acid(µmol/L) | 319.16 ± 116.27 |
 Blood potassium level (mmol/L) | 4.16 ± 0.35 |
 HGB(g/L) | 122.34 ± 21.51 |
 h-CRP(mg/L) | 7.64 ± 6.27 |
 CKMB(ng/ml) | 13.71 ± 6.99 |
 FFA(mmol/l) | 0.43 ± 0.21 |
 Triglyceride (mg/dl) | 140.42 ± 76.13 |
 LDL-C (mmol/L) | 2.31 ± 0.89 |
 HDL-C(mmol/L) | 0.96 ± 0.33 |
 Total cholesterol level (mmol/L) | 3.96 ± 1.06 |
 HbA1c (%) | 5.56 ± 0.42 |
 Fasting blood glucose(mg/dl) | 95.37 ± 14.29 |
 WBC(10^9/L) | 8.12 ± 2.71 |
Comorbidities and risk factors | |
 Hypertension, n (%) | 212 (29.7%) |
 Dyslipidemia, n (%) | 159 (22.3%) |
 Atrial fibrillation, n (%) | 91 (12.8%) |
 Non- sustained ventricular tachycardia, n (%) | 19 (2.7%) |
 Smoking, n (%) | 297 (41.7%) |
 NYHA Class III or IV, n (%) | 90 (12.6%) |
Echocardiography | |
 Interventricular septal thickness (mm) | 19.97 ± 5.20 |
 LV end-diastolic diameter (mm) | 42.31 ± 5.97 |
 LV posterior wall thickness (mm) | 12.01 ± 2.97 |
 LV ejection fraction (%) | 67.85 ± 8.77 |
 LV outflow tract gradient, at rest (mmHg) | 74.24 ± 33.80 |
 Inner diameter of ascending aorta (mm) | 30.26 ± 9.25 |
 Left atrial anteroposterior diameter (mm) | 40.03 ± 13.12 |
 Left ventricular posterior wall thickness (mm) | 12.01 ± 2.97 |
 Anterior posterior diameter of right ventricle (mm) | 20.28 ± 4.67 |
Medications | |
 Beta-blocker, n (%) | 364 (51.1%) |
 ACEI/ARB, n (%) | 53 (7.4%) |
 Statin, n (%) | 86 (12.1%) |
 Calcium antagonist, n (%) | 107 (15.0%) |